{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:12:40Z","timestamp":1783901560661,"version":"3.55.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100015993","name":"Qom University of Medical Science","doi-asserted-by":"publisher","award":["14031849"],"award-info":[{"award-number":["14031849"]}],"id":[{"id":"10.13039\/501100015993","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004484","name":"Tehran University of Medical Sciences and Health Services","doi-asserted-by":"publisher","award":["1403-1-101-71572"],"award-info":[{"award-number":["1403-1-101-71572"]}],"id":[{"id":"10.13039\/501100004484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-42462-7","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T10:25:21Z","timestamp":1778149521000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Introducing tetracycline as a potential OXA-48 carbapenemase inhibitor: an in silico and in vitro approach"],"prefix":"10.1038","volume":"16","author":[{"given":"Hourieh","family":"Kalhor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mana","family":"Salehibarmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Siroosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"42462_CR1","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1128\/CMR.00037-09","volume":"23","author":"M Drawz Sarah","year":"2010","unstructured":"Drawz Sarah, M. & Bonomo Robert, A. Three decades of \u03b2-lactamase inhibitors. Clin. Microbiol. Rev. 23, 160\u2013201 (2010).","journal-title":"Clin. Microbiol. Rev."},{"key":"42462_CR2","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.12688\/f1000research.14822.1","volume":"7","author":"Z Pana","year":"2018","unstructured":"Pana, Z. & Zaoutis, T. Treatment of extended-spectrum \u03b2-lactamase-producing enterobacteriaceae (ESBLs) infections: What have we learned until now? F1000Research 7, 1347 (2018).","journal-title":"F1000Research"},{"key":"42462_CR3","doi-asserted-by":"publisher","first-page":"S48","DOI":"10.1086\/514922","volume":"27","author":"K Bush","year":"1998","unstructured":"Bush, K. Metallo-\u03b2-lactamases: A class apart. Clin. Infect. Dis. 27, S48\u2013S53 (1998).","journal-title":"Clin. Infect. Dis."},{"issue":"Pt 1","key":"42462_CR4","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1042\/bj2760269","volume":"276","author":"RP Ambler","year":"1991","unstructured":"Ambler, R. P. et al. A standard numbering scheme for the class A \u03b2-lactamases. Biochem. J. 276\u00a0(Pt 1), 269\u2013270. https:\/\/doi.org\/10.1042\/bj2760269 (1991).","journal-title":"Biochem. J."},{"key":"42462_CR5","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s10096-017-3112-7","volume":"37","author":"A Mairi","year":"2018","unstructured":"Mairi, A., Pantel, A., Sotto, A., Lavigne, J. P. & Touati, A. OXA-48-like carbapenemases producing Enterobacteriaceae in different niches. Eur. J. Clin. Microbiol. Infect. Dis. 37, 587\u2013604 (2018).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"42462_CR6","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1021\/acsinfecdis.1c00501","volume":"7","author":"DM Taylor","year":"2021","unstructured":"Taylor, D. M. et al. Unique diacidic fragments inhibit the OXA-48 carbapenemase and enhance the killing of Escherichia coli producing OXA-48. ACS Infect. Dis. 7, 3345\u20133354 (2021).","journal-title":"ACS Infect. Dis."},{"key":"42462_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1128\/AAC.48.1.15-22.2004","volume":"48","author":"L Poirel","year":"2004","unstructured":"Poirel, L., H\u00e9ritier, C., Tol\u00fcn, V. & Nordmann, P. Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob. Agents Chemother. 48, 15\u201322 (2004).","journal-title":"Antimicrob. Agents Chemother."},{"key":"42462_CR8","doi-asserted-by":"publisher","first-page":"00102","DOI":"10.1128\/cmr","volume":"33","author":"JD Pitout","year":"2019","unstructured":"Pitout, J. D., Peirano, G., Kock, M. M., Strydom, K. A. & Matsumura, Y. The global ascendency of OXA-48-type carbapenemases. Clin. Microbiol. Rev. 33, 00102\u201300119. https:\/\/doi.org\/10.1128\/cmr (2019).","journal-title":"Clin. Microbiol. Rev."},{"key":"42462_CR9","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1080\/14787210.2020.1729126","volume":"18","author":"A Touati","year":"2020","unstructured":"Touati, A. & Mairi, A. Epidemiology of carbapenemase-producing Enterobacterales in the Middle East: A systematic review. Expert Rev. Anti Infect. Ther. 18, 241\u2013250 (2020).","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"42462_CR10","doi-asserted-by":"publisher","first-page":"S565","DOI":"10.1093\/cid\/ciz830","volume":"69","author":"Y Doi","year":"2019","unstructured":"Doi, Y. Treatment options for carbapenem-resistant gram-negative bacterial infections. Clin. Infect. Dis. 69, S565\u2013S575 (2019).","journal-title":"Clin. Infect. Dis."},{"key":"42462_CR11","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1007\/s10096-021-04296-1","volume":"40","author":"K Tompkins","year":"2021","unstructured":"Tompkins, K. & van Duin, D. Treatment for carbapenem-resistant Enterobacterales infections: Recent advances and future directions. Eur. J. Clin. Microbiol. Infect. Dis. 40, 2053\u20132068 (2021).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"42462_CR12","doi-asserted-by":"crossref","unstructured":"Tilahun, M., Kassa, Y., Gedefie, A. & Ashagire, M. Emerging carbapenem-resistant Enterobacteriaceae infection, its epidemiology and novel treatment options: A review. Infect. Drug Resist. 4363\u20134374 (2021).","DOI":"10.2147\/IDR.S337611"},{"key":"42462_CR13","doi-asserted-by":"crossref","unstructured":"Mishra, S. K., Roy, S., Chhetri, T. & Georrge, J. J. Computer-assisted methods and tools for structure\u2010and ligand\u2010based drug design. Comput. Methods Rat. Drug Des. 69\u201395 (2025).","DOI":"10.1002\/9781394249190.ch4"},{"key":"42462_CR14","unstructured":"Mishra, S. K., Sharma, K. & Georrge, J. J. Antimicrobial resistance: Enzymes, proteins, and computational resources. Curr. Pharm. Des. (2025)."},{"key":"42462_CR15","doi-asserted-by":"publisher","first-page":"137473","DOI":"10.1016\/j.molstruc.2023.137473","volume":"1302","author":"FA Ugbe","year":"2024","unstructured":"Ugbe, F. A. et al. Computational evaluation of the inhibitory potential of some urea, thiourea, and selenourea derivatives of diselenides against leishmaniasis: 2D-QSAR, pharmacokinetics, molecular docking, and molecular dynamics simulation. J. Mol. Struct. 1302, 137473 (2024).","journal-title":"J. Mol. Struct."},{"key":"42462_CR16","doi-asserted-by":"crossref","unstructured":"Edache, E. I. et al. Pharmacophore modeling, 2D-QSAR, drug likeness and toxicity prediction of 2-aziridinyl-and 2, 3-bis (aziridinyl)-1, 4-naphthoquinonyl sulfonate and acylate derivatives as multifunctional agents for the treatment of malaria parasite, Plasmodium falciparum. NAM J. 100019 (2025).","DOI":"10.1016\/j.namjnl.2025.100019"},{"key":"42462_CR17","doi-asserted-by":"publisher","first-page":"15402","DOI":"10.1038\/s41598-025-96667-3","volume":"15","author":"SK Mishra","year":"2025","unstructured":"Mishra, S. K. et al. Computational analysis of lupenone derivatives as potential inhibitor of human papillomavirus oncoprotein E6 associated cervical cancer. Sci. Rep. 15, 15402 (2025).","journal-title":"Sci. Rep."},{"key":"42462_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s44371-024-00026-6","volume":"1","author":"FA Ugbe","year":"2024","unstructured":"Ugbe, F. A. et al. Cheminformatic evaluation of the multi-protein binding potential of some diselenide derivatives: A plausible drug discovery approach for leishmaniasis. Discov. Chem. 1, 1\u201326 (2024).","journal-title":"Discov. Chem."},{"key":"42462_CR19","doi-asserted-by":"crossref","unstructured":"Morris, G. M. & Lim-Wilby, M. In Molecular Modeling of Proteins 365\u2013382 (Springer, 2008).","DOI":"10.1007\/978-1-59745-177-2_19"},{"key":"42462_CR20","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.neuron.2018.08.011","volume":"99","author":"SA Hollingsworth","year":"2018","unstructured":"Hollingsworth, S. A. & Dror, R. O. Molecular dynamics simulation for all. Neuron 99, 1129\u20131143 (2018).","journal-title":"Neuron"},{"key":"42462_CR21","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.chembiol.2009.04.010","volume":"16","author":"JD Docquier","year":"2009","unstructured":"Docquier, J. D. et al. Crystal structure of the OXA-48 \u03b2-lactamase reveals mechanistic diversity among class D carbapenemases. Chem. Biol. 16, 540\u2013547 (2009).","journal-title":"Chem. Biol."},{"key":"42462_CR22","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/jcc.21256","volume":"30","author":"GM Morris","year":"2009","unstructured":"Morris, G. M. et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem. 30, 2785\u20132791 (2009).","journal-title":"J. Comput. Chem."},{"issue":"10","key":"42462_CR23","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1021\/ci200227u","volume":"51","author":"RA Laskowski","year":"2011","unstructured":"Laskowski, R. A. & Swindells, M. B. LigPlot+: Multiple ligand-protein interaction diagrams for drug discovery. J. Chem. Inf. Model. 51 (10), 2778\u20132786 (2011).","journal-title":"J. Chem. Inf. Model."},{"key":"42462_CR24","unstructured":"Schrodinger, L. The PyMOL molecular graphics system. Version 1.8 (2015)."},{"key":"42462_CR25","doi-asserted-by":"publisher","first-page":"D724","DOI":"10.1093\/nar\/gkae1030","volume":"53","author":"Y Feng","year":"2025","unstructured":"Feng, Y. et al. StreptomeDB 4.0: A comprehensive database of streptomycetes natural products enriched with protein interactions and interactive spectral visualization. Nucleic Acids Res. 53, D724\u2013D729 (2025).","journal-title":"Nucleic Acids Res."},{"key":"42462_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","volume":"23","author":"CA Lipinski","year":"1997","unstructured":"Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Del. Rev. 23, 3\u201325 (1997).","journal-title":"Adv. Drug Del. Rev."},{"key":"42462_CR27","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1758-2946-3-33","volume":"3","author":"NM O\u2019Boyle","year":"2011","unstructured":"O\u2019Boyle, N. M. et al. Open babel: An open chemical toolbox. J. Cheminform. 3, 33 (2011).","journal-title":"J. Cheminform"},{"key":"42462_CR28","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.1021\/acs.jcim.1c00203","volume":"61","author":"J Eberhardt","year":"2021","unstructured":"Eberhardt, J., Santos-Martins, D., F Tillack, A. & Forli, S. AutoDock Vina 1.2.0: New docking methods, expanded force field, and python bindings. J. Chem. Inf. Model. 61, 3891\u20133898 (2021).","journal-title":"J. Chem. Inf. Model."},{"key":"42462_CR29","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott, O. & Olson, A. J. AutoDock & vina improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31, 455\u2013461 (2010).","journal-title":"J. Comput. Chem."},{"key":"42462_CR30","doi-asserted-by":"publisher","first-page":"1254230","DOI":"10.3389\/fmolb.2023.1254230","volume":"10","author":"EI Edache","year":"2023","unstructured":"Edache, E. I. et al. Combining docking, molecular dynamics simulations, AD-MET pharmacokinetics properties, and MMGBSA calculations to create specialized protocols for running effective virtual screening campaigns on the autoimmune disorder and SARS-CoV-2 main protease. Front. Mol. Biosci. 10, 1254230 (2023).","journal-title":"Front. Mol. Biosci."},{"key":"42462_CR31","doi-asserted-by":"publisher","first-page":"13830","DOI":"10.1080\/07391102.2023.2279269","volume":"42","author":"FA Ugbe","year":"2024","unstructured":"Ugbe, F. A. et al. Cheminformatics-based discovery of new organoselenium compounds with potential for the treatment of cutaneous and visceral leishmaniasis. J. Biomol. Struct. Dyn. 42, 13830\u201313853 (2024).","journal-title":"J. Biomol. Struct. Dyn."},{"key":"42462_CR32","unstructured":"Biovia, D. S. Discovery studio modeling environment. San Diego: Dassault Syst\u00e8mes (2024). V24.1.0334."},{"key":"42462_CR33","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","volume":"1","author":"MJ Abraham","year":"2015","unstructured":"Abraham, M. J. et al. GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 1, 19\u201325 (2015).","journal-title":"SoftwareX"},{"key":"42462_CR34","unstructured":"P\u00e1ll, S., Abraham, M. J., Kutzner, C., Hess, B. & Lindahl, E. In International Conference on Exascale Applications and Software. 3\u201327 (Springer)."},{"key":"42462_CR35","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1002\/jcc.20291","volume":"26","author":"D Van Der Spoel","year":"2005","unstructured":"Van Der Spoel, D. et al. GROMACS: Fast, flexible, and free. J. Comput. Chem. 26, 1701\u20131718 (2005).","journal-title":"J. Comput. Chem."},{"key":"42462_CR36","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1002\/jcc.21816","volume":"32","author":"V Zoete","year":"2011","unstructured":"Zoete, V., Cuendet, M. A., Grosdidier, A. & Michielin, O. SwissParam: A fast force field generation tool for small organic molecules. J. Comput. Chem. 32, 2359\u20132368 (2011).","journal-title":"J. Comput. Chem."},{"key":"42462_CR37","doi-asserted-by":"crossref","unstructured":"Vald\u00e9s-Tresanco, M., Vald\u00e9s-Tresanco, M., Valiente, P., Moreno Frias, E. & gmx_MMPBSA a new tool to perform end-state free energy calculations with GROMACS. J. Chem. Theory Comput. 17, 6281\u20136291 (2021).","DOI":"10.1021\/acs.jctc.1c00645"},{"key":"42462_CR38","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1517\/17460441.2015.1032936","volume":"10","author":"S Genheden","year":"2015","unstructured":"Genheden, S. & Ryde, U. The MM\/PBSA and MM\/GBSA methods to estimate ligand-binding affinities. Expert Opin. Drug Discov. 10, 449\u2013461 (2015).","journal-title":"Expert Opin. Drug Discov"},{"key":"42462_CR39","doi-asserted-by":"publisher","first-page":"e0335756","DOI":"10.1371\/journal.pone.0335756","volume":"20","author":"M Siroosi","year":"2025","unstructured":"Siroosi, M. et al. Investigating the impact of type IE CRISPR-Cas systems and acrEI10 on multidrug-resistance in clinical isolates of Klebsiella pneumoniae. PloS One. 20, e0335756 (2025).","journal-title":"PloS One"},{"key":"42462_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1006\/mpat.2002.0499","volume":"33","author":"C Yin-Ching","year":"2002","unstructured":"Yin-Ching, C., Jer-Horng, S., Ching-Nan, L. & Ming-Chung, C. Cloning of a gene encoding a unique haemolysin from Klebsiella pneumoniae and its potential use as a species-specific gene probe. Microb. Pathog. 33, 1\u20136 (2002).","journal-title":"Microb. Pathog"},{"key":"42462_CR41","unstructured":"CLSI. Performance standards for antimicrobial susceptibility testing CLSI document M100-S33. Clinical and Laboratory Standards Institute, Wayne, PA (2023)."},{"key":"42462_CR42","unstructured":"European Committee on Antimicrobial Susceptibility Testing. Breakpoint Tables for Interpretation of MICs and Zone Diameters, Version 15.0. (2025). https:\/\/www.eucast.org\/clinical_breakpoints"},{"key":"42462_CR43","unstructured":"Leber, A. L. In Clinical Microbiology Procedures Handbook (ASM, 2023)."},{"key":"42462_CR44","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1093\/infdis\/137.2.122","volume":"137","author":"M Berenbaum","year":"1978","unstructured":"Berenbaum, M. A method for testing for synergy with any number of agents. J. Infect. Dis. 137, 122\u2013130 (1978).","journal-title":"J. Infect. Dis."},{"key":"42462_CR45","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3390\/antibiotics10010089","volume":"10","author":"M Rivera-Izquierdo","year":"2021","unstructured":"Rivera-Izquierdo, M. et al. OXA-48 carbapenemase-producing enterobacterales in spanish hospitals: An updated comprehensive review on a rising antimicrobial resistance. Antibiotics 10, 89 (2021).","journal-title":"Antibiotics"},{"issue":"7","key":"42462_CR46","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1093\/jac\/dks121","volume":"67","author":"L Poirel","year":"2012","unstructured":"Poirel, L., Potron, A. & Nordmann, P. OXA-48-like carbapenemases: The phantom menace. J. Antimicrob. Chemother. 67 (7), 1597\u20131606 (2012).","journal-title":"J. Antimicrob. Chemother."},{"key":"42462_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11033-025-10774-y","volume":"52","author":"S Halimi","year":"2025","unstructured":"Halimi, S. & Siroosi, M. Prevalence of carbapenemase genes in Klebsiella pneumoniae and Escherichia coli isolated from intensive care unit patients in Iran: A systematic review (2014\u20132025). Mol. Biol. Rep. 52, 1\u20139 (2025).","journal-title":"Mol. Biol. Rep."},{"key":"42462_CR48","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1021\/acsinfecdis.0c00015","volume":"6","author":"DM Taylor","year":"2020","unstructured":"Taylor, D. M. et al. Identifying oxacillinase-48 carbapenemase inhibitors using DNA-encoded chemical libraries. ACS Infect. Dis. 6, 1214\u20131227 (2020).","journal-title":"ACS Infect. Dis."},{"key":"42462_CR49","doi-asserted-by":"publisher","first-page":"926104","DOI":"10.3389\/fphar.2022.926104","volume":"13","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y. et al. Discovery of quercetin and its analogs as potent OXA-48 beta-lactamase inhibitors. Front. Pharmacol. 13, 926104 (2022).","journal-title":"Front. Pharmacol."},{"key":"42462_CR50","doi-asserted-by":"crossref","unstructured":"Sadeghi, S., Faramarzi, M. A. & Siroosi, M. Design of novel human microbiome-derived peptides for Inhibition of OXA-48 carbapenemase: An In-Silico and In-Vitro approach. Microb Pathog, 107779 (2025).","DOI":"10.1016\/j.micpath.2025.107779"},{"key":"42462_CR51","first-page":"688","volume":"2","author":"EI Edache","year":"2024","unstructured":"Edache, E. I., Uzairu, A., Mamza, P. A., Shallangwa, G. A. & Ibrahim, M. T. Design of some potent non-toxic autoimmune disorder inhibitors based on 2D-QSAR, CoMFA, molecular docking, and molecular dynamics investigations. Intell. Pharm. 2, 688\u2013706 (2024).","journal-title":"Intell. Pharm."},{"key":"42462_CR52","doi-asserted-by":"publisher","first-page":"229","DOI":"10.33084\/bjop.v6i3.4915","volume":"6","author":"EI Edache","year":"2023","unstructured":"Edache, E. I., Uzairu, A., Mamza, P. A. & Shallangwa, G. A. 2D-QSAR, docking, molecular dynamics simulations with the MM\/GBSA approaches against graves\u2019 disease and PTPN22. Borneo J. Pharm. 6, 229\u2013248 (2023).","journal-title":"Borneo J. Pharm."},{"key":"42462_CR53","doi-asserted-by":"publisher","first-page":"9","DOI":"10.33435\/tcandtc.1003157","volume":"6","author":"EI Edache","year":"2022","unstructured":"Edache, E. I. et al. Investigation of salicylidene acylhydrazides derivatives: Molecular docking, ADMET, and molecular dynamic simulations were used in conjunction towards the design of new Yersinia pseudotuberculosis inhibitors. Turk. Comput. Theor. Chem. 6, 9\u201330 (2022).","journal-title":"Turk. Comput. Theor. Chem."},{"key":"42462_CR54","doi-asserted-by":"publisher","first-page":"49","DOI":"10.26480\/asm.02.2024.61.73","volume":"8","author":"FA Ugbe","year":"2024","unstructured":"Ugbe, F. A., Ayuba, A. M., Edache, E. I., Jibrin, A. & Amusan, O. T. Evaluation of the anti-leishmanial potential of some prominent lead compounds against pyridoxal kinase in complex with adenosine diphosphate and pyridoxine: A comparative study. Acta Sci. Malays. 8, 49\u201351 (2024).","journal-title":"Acta Sci. Malays"},{"key":"42462_CR55","doi-asserted-by":"publisher","first-page":"57","DOI":"10.4274\/mjima.galenos.2021.2021.57","volume":"10","author":"A Sert\u00e7elik","year":"2021","unstructured":"Sert\u00e7elik, A., Baran, I., Ak\u0131nc\u0131, E., Kazanc\u0131o\u011flu, S. & Bodur, H. Evaluation of in vitro synergistic activities of some antibiotic combinations containing colistin, meropenem, vancomycin, and minocycline against oxacillinase-48 carbapenemase-producing klebsiella pneumoniae. Mediterr. J. Infect. Microbes Antimicrob. 10, 57\u201357 (2021).","journal-title":"Mediterr. J. Infect. Microbes Antimicrob."},{"key":"42462_CR56","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s00018-009-0172-6","volume":"67","author":"M Thaker","year":"2010","unstructured":"Thaker, M., Spanogiannopoulos, P. & Wright, G. D. The tetracycline resistome. Cell. Mol. Life Sci. 67, 419\u2013431 (2010).","journal-title":"Cell. Mol. Life Sci."},{"key":"42462_CR57","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/0092-8674(80)90321-9","volume":"20","author":"D Koshland","year":"1980","unstructured":"Koshland, D. & Botstein, D. Secretion of beta-lactamase requires the carboxy end of the protein. Cell 20, 749\u2013760 (1980).","journal-title":"Cell"},{"key":"42462_CR58","doi-asserted-by":"publisher","first-page":"6856","DOI":"10.1074\/jbc.270.12.6856","volume":"270","author":"H Yerushalmi","year":"1995","unstructured":"Yerushalmi, H., Lebendiker, M. & Schuldiner, S. EmrE, an Escherichia coli 12-kDa multidrug transporter, exchanges toxic cations and H\u2009+\u2009and is soluble in organic solvents. J. Biol. Chem. 270, 6856\u20136863 (1995).","journal-title":"J. Biol. Chem."},{"key":"42462_CR59","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.3389\/fmicb.2018.01058","volume":"9","author":"JL Markley","year":"2018","unstructured":"Markley, J. L. & Wencewicz, T. A. Tetracycline-inactivating enzymes. Front. Microbiol. 9, 1058 (2018).","journal-title":"Front. Microbiol."},{"key":"42462_CR60","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1093\/jac\/dkw105","volume":"71","author":"JA Vallejo","year":"2016","unstructured":"Vallejo, J. A. et al. LN-1-255, a penicillanic acid sulfone able to inhibit the class D carbapenemase OXA-48. J. Antimicrob. Chemother. 71, 2171\u20132180 (2016).","journal-title":"J. Antimicrob. Chemother."},{"key":"42462_CR61","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1208\/s12248-012-9390-1","volume":"14","author":"T Oprea","year":"2012","unstructured":"Oprea, T. & Mestres, J. Drug repurposing: Far beyond new targets for old drugs. AAPS J. 14, 759\u2013763 (2012).","journal-title":"AAPS J."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42462-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42462-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42462-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:02:41Z","timestamp":1783900961000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42462-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["42462"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-42462-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"3 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors are grateful to the Ethics Committee of Tehran University of Medical Sciences for their approval of this study (Ethics code: IR.TUMS.MEDICINE.REC.1403.100).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"21690"}}